Pedro M. Sanz-Altamira, MD, PhD - Dana ...

Dr. Pedro M. Sanz-Altamira

Claim this profile

Dana Farber-Merrimack Valley

Studies Breast Cancer
Studies Lung Cancer
18 reported clinical trials
38 drugs studied

Area of expertise

1Breast Cancer
Pedro M. Sanz-Altamira has run 6 trials for Breast Cancer. Some of their research focus areas include:
HER2 positive
ER positive
HER2 negative
2Lung Cancer
Pedro M. Sanz-Altamira has run 5 trials for Lung Cancer. Some of their research focus areas include:
Stage II
Stage III
Stage I

Affiliated Hospitals

Image of trial facility.
Dana Farber-Merrimack Valley
Image of trial facility.
Dana-Farber Cancer Instiute - Merrimack Valley

Clinical Trials Pedro M. Sanz-Altamira is currently running

Image of trial facility.

Chemotherapy + Immunotherapy

for Esophageal and Gastric Cancer

This phase III trial compares the effect of modified fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan (mFOLFIRINOX) to modified fluorouracil, leucovorin calcium, and oxaliplatin (mFOLFOX) for the treatment of advanced, unresectable, or metastatic HER2 negative esophageal, gastroesophageal junction, and gastric adenocarcinoma. The usual approach for patients is treatment with FOLFOX chemotherapy. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Fluorouracil stops cells from making DNA and it may kill tumor cells. Leucovorin is used with fluorouracil to enhance the effects of the drug. Oxaliplatin works by killing, stopping, or slowing the growth of tumor cells. Some patients also receive an immunotherapy drug, nivolumab, in addition to FOLFOX chemotherapy. Immunotherapy may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Irinotecan blocks certain enzymes needed for cell division and DNA repair, and it may kill tumor cells. Adding irinotecan to the FOLFOX regimen could shrink the cancer and extend the life of patients with advanced gastroesophageal cancers.
Recruiting2 awards Phase 32 criteria
Image of trial facility.

Crizotinib

for Non-Small Cell Lung Cancer

This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria

More about Pedro M. Sanz-Altamira

Clinical Trial Related2 years of experience running clinical trials · Led 18 trials as a Principal Investigator · 9 Active Clinical Trials
Treatments Pedro M. Sanz-Altamira has experience with
  • Paclitaxel
  • Placebo
  • Abemaciclib
  • Tamoxifen
  • Exemestane
  • Trastuzumab

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Pedro M. Sanz-Altamira specialize in?
Is Pedro M. Sanz-Altamira currently recruiting for clinical trials?
Are there any treatments that Pedro M. Sanz-Altamira has studied deeply?
What is the best way to schedule an appointment with Pedro M. Sanz-Altamira?
What is the office address of Pedro M. Sanz-Altamira?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security